EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nuvation Bio's enterprise value is $56.40 Mil.
Nuvation Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-99.60 Mil. Therefore, Nuvation Bio's EV-to-EBITDA for today is -0.57.
The historical rank and industry rank for Nuvation Bio's EV-to-EBITDA or its related term are showing as below:
NUVB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.47 Med: 0 Max: 6.72
Current: -0.57
During the past 4 years, the highest EV-to-EBITDA of Nuvation Bio was 6.72. The lowest was -6.47. And the median was 0.00.
NUVB's EV-to-EBITDA is ranked worse than 100% of 470
companies
in the Biotechnology industry
Industry Median: 9.07
vs NUVB: -0.57
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-18), Nuvation Bio's stock price is $2.58.
Nuvation Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.350. Therefore, Nuvation Bio's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Nuvation Bio EV-to-EBITDA Historical Data
The historical data trend for Nuvation Bio's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Nuvation Bio Annual Data
Trend
Dec20
Dec21
Dec22
Dec23
EV-to-EBITDA
-
-
1.98
2.78
Nuvation Bio Quarterly Data
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-EBITDA
1.98
2.37
2.20
3.12
2.78
Competitive Comparison
For the Biotechnology subindustry, Nuvation Bio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvation Bio EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Nuvation Bio's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nuvation Bio's EV-to-EBITDA falls into.
Nuvation Bio EV-to-EBITDA Calculation
Nuvation Bio's EV-to-EBITDA for today is calculated as:
Nuvation Bio's current Enterprise Value is $56.40 Mil.
Nuvation Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-99.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvation Bio (NYSE:NUVB) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Nuvation Bio's PE Ratio for today is calculated as:
Nuvation Bio's share price for today is $2.58.
Nuvation Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.350.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Nuvation Bio's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NUVB has been successfully added to your 